We Think That There Are Issues Underlying Bellevue Gold's (ASX:BGL) Earnings
Bellevue Gold Limited (ASX:BGL) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders have noticed something concerning in the numbers.
Check out our latest analysis for Bellevue Gold
One essential aspect of assessing earnings quality is to look at how much a company is diluting shareholders. As it happens, Bellevue Gold issued 9.0% more new shares over the last year. That means its earnings are split among a greater number of shares. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. You can see a chart of Bellevue Gold's EPS by clicking here.
Bellevue Gold was losing money three years ago. Zooming in to the last year, we still can't talk about growth rates coherently, since it made a loss last year. But mathematics aside, it is always good to see when a formerly unprofitable business come good (though we accept profit would have been higher if dilution had not been required). So you can see that the dilution has had a bit of an impact on shareholders.
In the long term, if Bellevue Gold's earnings per share can increase, then the share price should too. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Bellevue Gold issued shares during the year, and that means its EPS performance lags its net income growth. Because of this, we think that it may be that Bellevue Gold's statutory profits are better than its underlying earnings power. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. While it's really important to consider how well a company's statutory earnings represent its true earnings power, it's also worth taking a look at what analysts are forecasting for the future. So feel free to check out our free graph representing analyst forecasts.
This note has only looked at a single factor that sheds light on the nature of Bellevue Gold's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
2 hours ago
- Business Insider
UBS Sticks to Its Sell Rating for ASX (ASXFF)
UBS analyst Kieren Chidgey maintained a Sell rating on ASX (ASXFF – Research Report) today and set a price target of A$69.10. The company's shares closed last Tuesday at $45.35. Confident Investing Starts Here: Chidgey covers the Financial sector, focusing on stocks such as ASX , Insurance Australia Group Limited, and QBE Insurance Group Limited. According to TipRanks, Chidgey has an average return of -0.4% and a 52.38% success rate on recommended stocks. In addition to UBS, ASX also received a Sell from Morgan Stanley's Andrei Stadnik in a report issued yesterday. However, on the same day, Citi maintained a Hold rating on ASX (Other OTC: ASXFF).


Business Insider
3 hours ago
- Business Insider
ASX (ASXFF) Gets a Hold from Citi
Citi analyst Nigel Pittaway maintained a Hold rating on ASX (ASXFF – Research Report) today and set a price target of A$71.60. The company's shares closed last Tuesday at $45.35. Confident Investing Starts Here: According to TipRanks, Pittaway is a 4-star analyst with an average return of 3.6% and a 57.44% success rate. Pittaway covers the Financial sector, focusing on stocks such as Challenger , QBE Insurance Group Limited, and ASX . The word on The Street in general, suggests a Moderate Sell analyst consensus rating for ASX with a $42.99 average price target. The company has a one-year high of $50.05 and a one-year low of $36.25. Currently, ASX has an average volume of 641.
Yahoo
4 hours ago
- Yahoo
ASX Penny Stocks: EMVision Medical Devices Leads Our Trio Of Picks
As Australian shares are set to advance slightly, buoyed by positive U.S. inflation data and a stable commodities market, investors are keenly observing the opportunities within the local stock landscape. Despite its vintage feel, the term 'penny stocks' continues to hold relevance for those interested in smaller or newer companies that offer both affordability and growth potential. In this article, we explore three penny stocks that stand out for their financial strength and potential for long-term value creation. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.735 A$81.85M ★★★★★★ GTN (ASX:GTN) A$0.605 A$115.47M ★★★★★★ IVE Group (ASX:IGL) A$2.76 A$425.54M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.10 A$730.43M ★★★★★☆ Regal Partners (ASX:RPL) A$2.22 A$746.28M ★★★★★★ Accent Group (ASX:AX1) A$1.805 A$1.09B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.705 A$223.61M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.27 A$155.16M ★★★★★★ CTI Logistics (ASX:CLX) A$1.79 A$144.17M ★★★★☆☆ Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, along with other medical imaging needs in Australia, with a market cap of A$156.92 million. Operations: The company generates revenue primarily from the research and development of medical device technology, amounting to A$8.06 million. Market Cap: A$156.92M EMVision Medical Devices Ltd, with a market cap of A$156.92 million, remains pre-revenue as it focuses on developing its neurodiagnostic technology. The company has more cash than debt and maintains a stable cash runway exceeding one year. Recent developments include the commencement of a pivotal trial for its emu™ Brain Scanner, aimed at stroke diagnosis and potentially supporting FDA clearance. This trial could pave the way for future product expansions in the medical imaging field. EMVision's board recently welcomed Carmel Monaghan as an Independent Non-Executive Director, bringing extensive healthcare experience to support strategic growth initiatives. Unlock comprehensive insights into our analysis of EMVision Medical Devices stock in this financial health report. Explore historical data to track EMVision Medical Devices' performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: LGI Limited focuses on carbon abatement and renewable energy solutions using biogas from landfill, with a market cap of A$267.31 million. Operations: The company generates revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Market Cap: A$267.31M LGI Limited, with a market cap of A$267.31 million, is generating revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Despite the company's earnings contracting by 15.3% over the past year, its debt management remains strong with operating cash flow covering 34.4% of its debt and a reduced debt-to-equity ratio from 146.5% to 46.2% over five years. While LGI's net profit margin has decreased to 17.4%, it maintains stable weekly volatility at 4%. The board is experienced, though management tenure averages only 1.3 years. Click here to discover the nuances of LGI with our detailed analytical financial health report. Understand LGI's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: NRW Holdings Limited, with a market cap of A$1.36 billion, offers diversified contract services to the resources and infrastructure sectors in Australia through its subsidiaries. Operations: NRW Holdings generates revenue from three main segments: Mining at A$1.56 billion, MET at A$853.22 million, and Civil at A$776.06 million. Market Cap: A$1.36B NRW Holdings, with a market cap of A$1.36 billion, demonstrates strong financial health through well-covered interest payments and operating cash flow that exceeds its debt by a large margin. The company's earnings have grown significantly by 29.9% over the past year, surpassing both its historical average and industry growth rates. Despite having low return on equity at 17.3%, NRW is trading below estimated fair value and has not diluted shareholders recently. Short-term assets exceed liabilities, indicating robust liquidity management, while recent executive changes bring seasoned leadership to the finance team with Peter Bryant as CFO starting in May 2025. Navigate through the intricacies of NRW Holdings with our comprehensive balance sheet health report here. Evaluate NRW Holdings' prospects by accessing our earnings growth report. Click this link to deep-dive into the 1,006 companies within our ASX Penny Stocks screener. Looking For Alternative Opportunities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EMV ASX:LGI and ASX:NWH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio